|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 189.62 USD | -0.70% |
|
+4.75% | +106.27% |
| 06-30 | Astrazeneca Reports Positive MULBERRY Phase III Results For Efzimfotase Alfa In Pediatric Hypophosphatasia | CI |
| 06-30 | Rising Stockholm market closed near the day's high, OMXS30 index up 1.2% | FW |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 1,220.39 | -0.78% | 28 | ||||||
| 257.5 | -0.39% | 22 | ||||||
| 256.14 | +0.72% | 28 | ||||||
| 358.83 | +5.91% | 18 | ||||||
| 154.49 | -1.05% | 21 | ||||||
| 315.24 | +0.11% | 24 | ||||||
| 354.76 | -1.61% | 29 | ||||||
| 157.67 | +24.81% | 27 | ||||||
| 29.15 | +19.62% | 27 | ||||||
| 548.69 | +9.81% | 29 | ||||||
| 63 | +7.58% | 24 | ||||||
| 20.92 | +5.69% | 19 | ||||||
| 96.7 | +28.09% | 23 | ||||||
| 9,973.33 | +31.68% | 15 | ||||||
| 81.14 | +53.29% | 16 | ||||||
| 6,106.87 | +17.98% | 15 | ||||||
| 4.136 | +18.73% | 17 | ||||||
| 434.72 | +48.11% | 25 | ||||||
| Average | 1,135.21 | +14.91% | 23 | ||||||
| Weighted average by Cap. | 744.27 | +5.14% | 25 |
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Sector AstraZeneca PLC
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
